The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Bone Loss after Initiation of Androgen Deprivation Therapy in Patients with Prostate Cancer
Abstract
Context: Although androgen deprivation therapy (ADT) for prostate cancer is associated with bone loss, little is known about when this bone loss occurs. Objective: We postulated that men on ADT would experience the greatest bone loss acutely after initiation of ADT. Design and Setting: We conducted a 12-month prospective study at an academic medical center. Patients or Other Participants: We studied 152 men with prostate cancer (30 with acute ADT, <6 months; 50 with chronic ADT, ≥6 months; and 72 with no ADT) and 43 healthy age-matched controls. Main Outcome Measures: We assessed bone mineral density (BMD) of the hip, wrist, total body, and spine; body composition; and markers of bone turnover. Results: After 12 months, men receiving acute ADT had a significant reduction in BMD of 2.5 ± 0.6% at the total hip, 2.4 ± 1.0% at the trochanter, 2.6 ± 0.5% at the total radius, 3.3 ± 0.5% at the total body, and 4.0 ± 1.5% at the posteroanterior spine (all P < 0.05). Men with chronic ADT had a 2.0 ± 0.6% reduction in BMD at the total radius (P < 0.05). Healthy controls and men with prostate cancer not receiving ADT had no significant reduction in BMD. Both use and duration of ADT were associated with change in bone mass at the hip (P < 0.05). Men receiving acute ADT had a 10.4 ± 1.7% increase in total body fat and a 3.5 ± 0.5% reduction in total body lean mass at 12 months, whereas body composition did not change in men with prostate cancer on chronic ADT or in healthy controls (P < 0.05). Markers of bone formation and resorption were elevated in men receiving acute ADT after 6 and 12 months compared with the other men with prostate cancer and controls (P < 0.05). Men in the highest tertile of bone turnover markers at 6 months had the greatest loss of bone density at 12 months. Conclusions: Men with prostate cancer who are initiating ADT have a 5- to 10-fold increased loss of bone density at multiple skeletal sites compared with either healthy controls or men with prostate cancer who are not on ADT, placing them at increased risk of fracture. Bone loss is maximal in the first year after initiation of ADT, suggesting initiation of early preventive therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Kanis, J. A., & Kanis, J. A. (1994) · Osteoporosis International · doi:10.1007/bf01622200 · Cited by 2,516
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., & Goodwin, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041943 · Cited by 1,375
Applied Mixed Models in Medicine
Brown, H., & Presco, R. (2000) · Technometrics · doi:10.1080/00401706.2000.10485742 · Cited by 1,262
Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412401 · Cited by 1,191
Self-citationEffect of testosterone and estradiol in a man with aromatase deficiency
Carani, C., Qin, K., Simoni, M., Faustini-Fustini, M., Serpente, S., Boyd, J., Korach, K. S., & Simpson, E. R. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707103370204 · Cited by 1,151
Androgen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,083
Falahati-Nini, A., Riggs, B. L., Atkinson, E. J., O’Fallon, W. M., Eastell, R., & Khosla, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10942 · Cited by 757
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697
Bone Density and Fracture Risk in Men
Dr. Melton, L. J., Atkinson, E. J., O'Connor, M. K., O'Fallon, W. M., & Riggs, B. L. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.12.1915 · Cited by 684
SMITH, M. R., EASTHAM, J., GLEASON, D. M., SHASHA, D., TCHEKMEDYIAN, S., & ZINNER, N. (2003) · Journal of Urology · doi:10.1097/01.ju.0000063820.94994.95 · Cited by 650
Increased Bone Mass as a Result of Estrogen Therapy in a Man with Aromatase Deficiency
Bilezikian, J. P., Morishima, A., Bell, J., & Grumbach, M. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390905 · Cited by 625
Khosla, S. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.8.3555 · Cited by 522
PROGRESSIVE OSTEOPOROSIS DURING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER
DANIELL, H. W., DUNN, S. R., FERGUSON, D. W., LOMAS, G., NIAZI, Z., & STRATTE, P. T. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)68000-7 · Cited by 452
Skeletal Fractures Negatively Correlate With Overall Survival in Men With Prostate Cancer
Oefelein, M. G., Ricchiuti, V., Conrad, W., & Resnick, M. I. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64561-2 · Cited by 347
RE: OSTEOPOROSIS AFTER ORCHIECTOMY FOR PROSTATE CANCER
Krongrad, A., Levis, S., & Roos, B. A. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64271-x · Cited by 339
BERRUTI, A., DOGLIOTTI, L., TERRONE, C., CERUTTI, S., ISAIA, G., TARABUZZI, R., REIMONDO, G., MARI, M., ARDISSONE, P., DE LUCA, S., et al. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64985-3 · Cited by 315
Osteoporosis After Orchiectomy for Prostate Cancer
Daniell, H. W. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)65165-6 · Cited by 315
Estrogen and the Male Skeleton
Khosla, S., Melton, L. J., & Riggs, B. L. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8417 · Cited by 308
MAILLEFERT, J. F., SIBILIA, J., MICHEL, F., SAUSSINE, C., JAVIER, R. M., & TAVERNIER, C. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)61639-2 · Cited by 308
ORWOLL, E. S., OVIATT, S. K., & MANN, T. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-4-1202 · Cited by 306
Amin, S., Zhang, Y., Sawin, C. T., Evans, S. R., Hannan, M. T., Kiel, D. P., Wilson, P. W. F., & Felson, D. T. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-12-200012190-00010 · Cited by 293
Bone Loss following Hypogonadism in Men with Prostate Cancer Treated with GnRH Analogs
Mittan, D. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.8.3656 · Cited by 278
Townsend, M. F., Sanders, W. H., Northway, R. O., & Graham, S. D. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970201)79:3<545::aid-cncr17>3.0.co;2-3 · Cited by 260
Diamond, T. H., Higano, C. S., Smith, M. R., Guise, T. A., & Singer, F. R. (2004) · Cancer · doi:10.1002/cncr.20056 · Cited by 255
Smith, M. R., Fallon, M. A., Lee, H., & Finkelstein, J. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032058 · Cited by 248
Characterization of the role of IL-6 in the progression of prostate cancer
Chung, T. D., Yu, J. J., Spiotto, M. T., Bartkowski, M., & Simons, J. W. (1999) · The Prostate · doi:10.1002/(sici)1097-0045(19990215)38:3<199::aid-pros4>3.0.co;2-h · Cited by 231
Diamond, T. H., Winters, J., Smith, A., De Souza, P., Kersley, J. H., Lynch, W. J., & Bryant, C. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6<1444::aid-cncr1468>3.0.co;2-m · Cited by 190
Hormonal and Biochemical Parameters in the Determination of Osteoporosis in Elderly Men*
Center, J. R., Nguyen, T. V., Sambrook, P. N., & Eisman, J. A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6051 · Cited by 189
Bone Loss in Men with Prostate Cancer Treated with Gonadotropin-Releasing Hormone Agonists1
Stoch, S. A., Parker, R. A., Chen, L., Bubley, G., Ko, Y.-J., Vincelette, A., & Greenspan, S. L. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7558 · Cited by 186
Self-citationKiratli, B. J., Srinivas, S., Perkash, I., & Terris, M. K. (2001) · Urology · doi:10.1016/s0090-4295(00)00895-5 · Cited by 172
Androgen deprivation therapy for prostate cancer results in significant loss of bone density
Wei, J. T., Gross, M., Jaffe, C. A., Gravlin, K., Lahaie, M., Faerber, G. J., & Cooney, K. A. (1999) · Urology · doi:10.1016/s0090-4295(99)00301-5 · Cited by 169
Osteoporosis in Men Treated With Androgen Deprivation Therapy for Prostate Cancer
ROSS, R. W., & SMALL, E. J. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)65060-4 · Cited by 161
Bone Loss in Men with Prostate Cancer Treated with Gonadotropin-Releasing Hormone Agonists
Stoch, S. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.6.2787 · Cited by 150
Osteoporosis in Men Treated With Androgen Deprivation Therapy for Prostate Cancer
Ross, R. W., & Small, E. J. (2002) · The Journal of Urology · doi:10.1097/00005392-200205000-00003 · Cited by 142
Fracture Risk Following Bilateral Orchiectomy
Melton, L. J., Alothman, K. I., Khosla, S., Achenbach, S. J., Oberg, A. L., & Zincke, H. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000059281.67667.97 · Cited by 136
Factors Predicting Fractures During Falling Impacts Among Home‐Dwelling Older Adults
Luukinen, H., Koski, K., Laippala, P. J., & Kivelä, S. (1997) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1997.tb02928.x · Cited by 109
Krupski, T. L., Smith, M. R., Lee, W. C., Pashos, C. L., Brandman, J., Wang, Q. L., Botteman, M. F., & Litwin, M. S. (2004) · Cancer · doi:10.1002/cncr.20388 · Cited by 109
Zhao, C., Maricic, M. J., Nguyen, P. L., Ahmann, F. R., Bruhn, R. L., & Dalkin, B. L. (2002) · Cancer · doi:10.1002/cncr.10967 · Cited by 104
Dietary calcium intake and bone loss from the spine in healthy postmenopausal women
Dawson‐Hughes, B., Jacques, P. F., & Shipp, C. (1987) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/46.4.685 · Cited by 101
DIAMOND, T. H., Bucci, J. A., Kersley, J. H., Aslan, P., LYNCH, W. B., & Bryant, C. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000130508.61020.66 · Cited by 69
Effect of radiographic abnormalities on rate of bone loss from the spine
Dawson‐Hughes, B., & Dallal, G. E. (1990) · Calcified Tissue International · doi:10.1007/bf02555008 · Cited by 65
HIP FRACTURES IN MEN WITH PROSTATE CANCER TREATED WITH ORCHIECTOMY
Dickman, P. W., Adolfsson, J., Åström, K. G. O., et al. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000143930.73016.c6 · Cited by 44
Taxel, P., FALL, P. M., Albertsen, P. C., Dowsett, R. D., Trahiotis, M., Zimmerman, J., Ohannessian, C. M., & Raisz, L. G. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020539 · Cited by 42
Bae, D. C., & Stein, B. S. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000141515.67372.e5 · Cited by 42
OSTEOPOROSIS AND OBESITY IN MEN RECEIVING HORMONE THERAPY FOR PROSTATE CANCER
Smith, M. R. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000141820.17959.2f · Cited by 38
Bouxsein, M., Parker, R. A., & Greenspan, S. L. (1999) · Osteoporosis International · doi:10.1007/s001980050261 · Cited by 35
Self-citation
Cited by
Khosla, S., Amin, S., & Orwoll, E. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0002 · Cited by 930
Galvão, D. A., Taaffe, D. R., Spry, N., Joseph, D., & Newton, R. U. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2488 · Cited by 657
Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline
Watts, N. B., Adler, R. A., Bilezikian, J. P., Drake, M. T., Eastell, R., Orwoll, E. S., & Finkelstein, J. S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3045 · Cited by 611
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Bone Turnover Markers: Basic Biology to Clinical Applications
Schini, M., Vilaca, T., Gossiel, F., Salam, S., & Eastell, R. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac031 · Cited by 387
Metadata
- Authors
- Greenspan, S. L., Coates, P., Sereika, S. M., Nelson, J. B., Trump, D. L., & Resnick, N. M.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-12-01
- Volume
- 90
- Issue
- 12
- Pages
- 6410-6417
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2129550487
- Cited by
- 411
- References
- 47
- FWCI
- 15.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.